News - Royalty Pharma
WEBAug 8, 2024 · Royalty Pharma Declares Third Quarter 2024 Dividend. Earnings. NEW YORK, NY, July 17, 2024 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of …
Royalty Pharma
WEBRoyalty Pharma Reports Second Quarter 2024 Results. Earnings. NEW YORK, NY, August 8, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts.
Royalty Pharma plc (RPRX) Latest Stock News & Headlines
WEBGet the latest Royalty Pharma plc (RPRX) stock news and headlines to help you in your trading and investing decisions.
Royalty Pharma announces FDA approval milestone
WEB6 days ago · In other recent news, Royalty Pharma has been making significant strides in its business operations. The company reported a robust 12% increase in Q2 portfolio receipts, surpassing its high-single digit growth forecast. Additionally, Royalty Pharma invested $2 billion in new royalty transactions and acquired royalties on six therapies.
Royalty Pharma Announces $2.025 Billion Strategic Funding …
WEBJun 2, 2021 · NEW YORK, NY, and PLANEGG, GERMANY, June 2, 2021 – Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys’ $1.7 billion acquisition of Constellation Pharmaceuticals.
Royalty Pharma Highlights Accomplishments and Provides …
WEBJan 8, 2024 · Royalty Pharma plc. 2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance range. Announced transactions of $13 billion since 2020 expected to...
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
WEBNEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it will acquire royalties and milestones on frexalimab owned by ImmuNext, Inc. (ImmuNext) for...
Royalty Pharma Highlights Accomplishments and ... - Markets …
WEBNEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2023...
Royalty Pharma (RPRX) Stock Price, News & Analysis - MarketBeat
WEB3 days ago · Should You Buy or Sell Royalty Pharma Stock? Get The Latest RPRX Stock Analysis, Price Target, Dividend Info, Headlines, and Short Interest at MarketBeat. Skip to main content
RPRX Stock Price | Royalty Pharma PLC Stock Quote (U.S.: Nasdaq ...
WEB2 days ago · RPRX | Complete Royalty Pharma PLC stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
- Some results have been removed